Treatment options for
metastatic urothelial carcinoma:
Highlights from the ASCO 22 Annual Meeting: an expert discussion with Andrea Apolo and Elizabeth Plimack
Andrea Apolo and Elizabeth Plimack discuss highlights of the ASCO 22 Annual Meeting. Here, they talk about some of the exciting new data presented on the use of antibody-drug conjugates targeting HER2, which are starting to show promise for the treatment of urothelial carcinoma (UC). They also review the use of tyrosine kinase inhibitors as agents in the metastatic setting, as outlined in two studies ATLANTIS and COSMIC-021. Finally, they comment on results indicating that DNA repair alterations can predict response to chemotherapy, as well as the general need for biomarkers to guide patient selection and treatment decisions.
Simon Crabb and Petros Grivas share their highlights from ASCO GU
Simon Crabb and Petros Grivas on the most interesting trials presented at ASCO GU 2022 in the field of urothelial carcinoma. They discuss emerging data in the neoadjuvant setting for cisplatin-ineligible patients, such as cohort H from the EV-103 trial, and the best sequencing strategy in upper-track disease setting. They also review the updates on metastatic disease highlighting the longer follow-up results from JAVELIN Bladder 100 and the interesting outcomes from the ATLANTIS trial. In the context of the BAYOU study, they talk about the importance of patient selection and the difficulty of writing the eligibility criteria for what platinum ineligibility really means. They also consider how the results from TROPHY-U-01 cohort 3 support further investigation and conclude that in this rapidly evolving setting, the future relies on combination therapy.
Recent developments in immunotherapy for patients with mUC (ESMO IO)
Michiel Van der Heijden and Ignacio Durán Martínez share their thoughts on the use of maintenance therapy after first-line chemotherapy for metastatic urothelial cancer and discuss new strategies in first line, such as single agent immunotherapy compared with chemotherapy and chemo-immuno combinations. They also comment on the upcoming results of the CheckMate 901 trial of nivolumab plus ipilimumab versus chemotherapy and highlight EV-302 study of enfortumab vedotin plus pembrolizumab compared with chemotherapy.
This independent programme is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany
All content has been developed independently by Springer Healthcare IME, in conjunction with an expert Faculty.